US2015374800A1PendingUtilityA1

Inhibitors of Branched-Chain-Aminotransferase-1 (BCAT1) for the Treatment of Brain Tumors

28
Assignee: DEUTSCHES KREBSFORSCHPriority: Jan 28, 2011Filed: Jun 26, 2015Published: Dec 31, 2015
Est. expiryJan 28, 2031(~4.5 yrs left)· nominal 20-yr term from priority
Inventors:Bernhard RadlwimmerMartje ToenjesSebastian BarbusPeter Lichter
A61P 35/00A61P 43/00C12N 2310/14A61K 31/195A61K 38/45A61K 31/7088C12N 15/113C12N 2310/11C12N 2310/531A61K 31/196C12Y 206/01042C07K 16/40C12N 15/1137A61P 25/00A61K 31/00A61K 39/39558A61K 31/713
28
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described is a compound capable of reducing or inhibiting (a) the biological activity of branched-chain-aminotrans-ferase-1 (BCATI) or (b) the expression of the gene encoding BCATI for use in a method of treating a neoplasia. A preferred compound is 1-(aminomethyl)cyclohexaneacetic acid (gabapentin).

Claims

exact text as granted — not AI-modified
1 .- 12 . (canceled) 
     
     
         13 . A pharmaceutical composition for treating a brain tumor, wherein said pharmaceutical composition comprises
 an effective dose of a compound capable of reducing or inhibiting
 (a) the biological activity of a branched-chain-aminotransferase-1 (BCAT1) or 
 (b) the expression of the gene encoding BCAT1, 
   
       wherein the effective dose leads to a reduction or inhibition of the proliferation of brain tumor cells in a subject,
 and a pharmaceutically acceptable carrier. 
 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein said compound is an antisense oligonucleotide or siRNA reducing or inhibiting the expression of the gene encoding BCAT1. 
     
     
         15 . The pharmaceutical composition of  claim 13 , wherein said compound is a compound reducing or inhibiting the biological activity of BCAT1. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein said compound is 1-(aminomethyl)cyclohexaneacetic acid. 
     
     
         17 . The pharmaceutical composition of  claim 15 , wherein said compound is an antibody directed against BCAT1 or a fragment thereof. 
     
     
         18 . The pharmaceutical composition of  claim 13 , wherein said compound is an inactive version of BCAT1. 
     
     
         19 . The pharmaceutical composition of  claim 13 , wherein said compound is, wherein the neoplasm to be treated shows BCAT1 (over) expression. 
     
     
         20 . The pharmaceutical composition of  claim 13 , wherein said compound is, wherein said brain tumor to be treated is an astrocytic brain tumor, glioma or glioblastoma. 
     
     
         21 . The pharmaceutical composition of  claim 20 , wherein said compound is, wherein the brain tumor is an IDHwt glioblastoma.

Join the waitlist — get patent alerts

Track US2015374800A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.